Princeton-based Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, announced Monday it has appointed Sally Allerheiligen to the newly-created position of senior vice president of health economics and education.
“Budget restrictions are a reality for governments, payers and patients alike and drug value is going to play a growing role in drug development and patient access decisions,” Certara CEO Edmundo Muniz said.
“Sandy is an expert at applying quantitative methods and systems pharmacology to experimental and real-world data to create drug-disease models that enable sponsors to make smart decisions. Her teams’ models are already used to inform drug discovery, preclinical, clinical and patient access decisions. At Certara, we are going to broaden the scope of that work and include payers in the discussion. We are excited to have Sandy as a senior leader on our team,” Muniz said.
“In the past, sponsors had to clear three hurdles to get a drug approved; they had to prove product safety, efficacy, and quality. Now, they need to overcome a fourth hurdle and demonstrate the product’s value to patients to ensure patient access and reimbursement,” Allerheiligen said. “Sponsors will have to negotiate with every health authority and payer and prove the value for patients. Model-informed drug development (MIDD) will provide sponsors with the quantitative data they need to make a successful case. I am delighted to join Certara because its vision will enable MIDD to reach its full potential.”
Allerheiligen previously served as vice president of data sciences and predictive and economic modeling for the Center for Observational and Real-World Evidence at Merck. She joined Merck in 2010 as vice president of modeling and simulation. Prior to that, she was global senior director of pharmacokinetics, pharmacodynamics and trial simulation; senior director of drug disposition; and distinguished fellow and chief scientific officer of quantitative pharmacology at Eli Lilly & Co.